Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation

Journal of Microbiology and Biotechnology

Volumn 11, Issue 4, 2001, Pages 619-627

  Kim, I S ^a   Choi, Y W ^a   Lee, S R ^a   Cho, H B ^a   Eo, H G ^a   Woo, H S ^a   Chang, C E ^a   Lee, S ^a  

^a Green Cross Company   (South Korea)

Author keywords

Cold ethanol fractionation; Human intravenous immunoglobulin; Low pH incubation; Pasteurization; Virus removal and inactivation

Indexed keywords

ALCOHOL; GLYCOL; IMMUNOGLOBULIN; POLYETHYLENE;

ARTICLE; BOVINE DIARRHEA VIRUS; BOVINE HERPES VIRUS; CONTROLLED STUDY; DRUG MANUFACTURE; FRACTIONATION; HUMAN; INCUBATION TIME; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PARVOVIRUS; PASTEURIZATION; PH; PRECIPITATION; SAFETY; SWINE; VIRUS ENVELOPE;

EID: 0034806740     PISSN: 10177825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat
2. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process
3. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids
4. The viral safety of intravenous immunoglobulin
5. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100°C
6. Immunoglobulins in autoimmunity: History and mechanism of action
7. Methodology and safety considerations in the production of an intravenous immunoglobulin preparation
8. Virus inactivation during intravenous immunoglobulin production
9. Expression and characterization of recombinant E2 protein of hepatitis C virus by insect cell/baculovirus expression system
10. Strategies to produce virus-safe blood derivatives
11. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates
12. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin: Availability
13. Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche
14. Virus inactivation during production of intravenous immunoglobulin
15. Large-scale culture of hepatitis A virus in human diploid MRC-5 cells and partial purification of the viral antigen for use as a vaccine
16. Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma
17. Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate
18. Non-A, non-B hepatitis from intravenous immunoglobulin
19. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin
20. Measures to inactivate viral contaminants of pooled plasma products
21. Inactivation of viruses and safety of stable plasma products
22. Virus safety of human immunoglobulins: Efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure
23. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization
24. Non-A non-B hepatitis and intravenous immunoglobulin
25. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: Factors affecting the rate of virus inactivation
26. 1-lipoprotein into subfractions of human plasma
27. Purification and characterization of recombinant hepatitis C virus replicase
28. Human parvovirus B19 and blood products
29. Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparation
30. Therapeutic uses of intravenous immunoglobilin (IVIg) in children
31. Potential contribution of mild pepsin treatment at pH 4 to the viral safety of human immunoglobulin products
32. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization
33. Characteristics and taxonomy of Parvoviridae
34. Human intravenous immunoglobulin in primary and secondary antibody deficiencies
35. Hepatitis C virus infection in hypogammaglobulinemic patients receiving long-term replacement therapy with intravenous immunoglobulin
36. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin
37. Non-A, non-B hepatitis after intravenous gammaglobulin
38. The viral safety of intravenous immune globulin